Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a ...
Total Revenue -- $164.9 million, up from $157.2 million the previous year; reflects increasing prescriptions and patient volume. Prescription Trends -- Record levels of new prescriptions, new patient ...
Moby summary of Axsome Therapeutics, Inc.'s Q1 2026 earnings call ...
Real-time continuous glucose monitoring (CGM) improves blood glucose management in adults with type 2 diabetes managed with ...
Corcept Therapeutics Incorporated is a Strong Buy after early FDA approval of Lyforli for PROC, with upside from EU decisions ...
Hosted on MSN
Master your chemistry lab skills with confidence
From safety protocols to mastering titration and spectroscopy, building strong chemistry lab skills is key to both academic success and future professional work. New approaches combine multimedia ...
Axsome Therapeutics (NASDAQ:AXSM) held its first-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive ...
Q1 2026. Management View "In the first quarter of 2026, Axsome delivered strong year-over-year growth and execution across the b ...
Most prescriptions in the United States get filled at one of three large chain pharmacies. The system works for the majority of patients most of the time. The system also ...
FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results